Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Joerger, M; Baty, F; Früh, M; Droege, C; Stahel, R A; Betticher, D C; von Moos, R; Ochsenbein, A; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, D; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer, 85(2):306-313.

Eisele, G; Wick, A; Eisele, A C; Clément, P M; Tonn, J; Tabatabai, G; Ochsenbein, A; Schlegel, U; Neyns, B; Krex, D; Simon, M; Nikkhah, G; Picard, M; Stupp, R; Wick, W; Weller, M (2014). Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 117(1):141-145.

Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.

von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mihic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23(2):531-536.

Schraml, P; von Teichman, A; Mihic-Probst, D; Simcock, M; Ochsenbein, A; Dummer, R; Michieilin, O; Seifert, B; Schläppi, M; Moch, H; von Moos, R (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 28(2):654-658.

Hofer, S; Elandt, K; Greil, R; Hottinger, A F; Huber, U; Lemke, D; Marosi, C; Ochsenbein, A; Pichler, J; Roelcke, U; Weder, P; Zander, T; Wick, W; Weller, M (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncologica, 50(5):630-635.

This list was generated on Thu Sep 20 11:30:47 2018 CEST.